Polyethylene Glycol 3350 in the Treatment of Chronic Idiopathic Constipation: Post hoc Analysis Using FDA Endpoints
- PMID: 36120087
- PMCID: PMC9481403
- DOI: 10.1155/2022/3533504
Polyethylene Glycol 3350 in the Treatment of Chronic Idiopathic Constipation: Post hoc Analysis Using FDA Endpoints
Abstract
Methods: This multicenter, double-blind, placebo-controlled, parallel-group trial included adults with chronic idiopathic constipation randomized to polyethylene glycol 3350 17 g (n = 204) or placebo (n = 100) once daily for 24 weeks. Post hoc analyses were performed using the US Food and Drug Administration endpoint (≥3 complete spontaneous bowel movements/week and an increase of ≥1 complete spontaneous bowel movement/week from baseline for ≥9/12 weeks, including 3 of the last 4 weeks) along with additional efficacy and safety outcomes.
Results: The proportion of patients meeting the new endpoint was significantly higher with polyethylene glycol 3350 vs placebo (42% vs 13%; P < 0.0001). Reductions in the mean number of hard/lumpy stools/week (-2.1 vs -0.9; P = 0.0014) and the weekly mean five-point cramping rating (-0.3 vs -0.1; P = 0.0272) also significantly favored polyethylene glycol 3350. The proportion of subjects with gastrointestinal adverse events decreased markedly after the first week of treatment in the polyethylene glycol 3350 group.
Conclusion: Using the current US Food and Drug Administration-recommended responder definition and other secondary outcomes, once-daily polyethylene glycol 3350 demonstrated substantial and sustained efficacy and safety over 24 weeks in patients with chronic idiopathic constipation. Trial Registration. The original trial was registered with https://clinicaltrials.gov Trial: NCT00153153.
Copyright © 2022 Stacy B. Menees et al.
Conflict of interest statement
The authors declare the following relevant interests: SM is a consultant of Takeda Pharmaceuticals. AJL is a consultant of Takeda, Allakos, Arena, Gemelli, Ironwood, RedHill, Bayer, Alkermes, QOL Medical, Vibrant, Mylan, Progenity, and BioAmerica; Stock ownership is of Johnson & Johnson, Bristol Myers Squibb, Rock West, and Allurion. WDC is a consultant of AbbVie, Alfasigma, Allakos, Alnylam, Arena, Biomerica, Ferring, Gemelli, Ironwood, Nestlé, Phathom, Progenity, RedHill, Ritter, Salix/Valeant, QOL Medical, Takeda, Urovant, and Vibrant; Grants include Commonwealth Diagnostics International, Biomerica, Salix, QOL Medical, and Vibrant; Stock options are GI OnDEMAND, ModifyHealth, and Ritter.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9481403/bin/CJGH2022-3533504.001.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9481403/bin/CJGH2022-3533504.002.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9481403/bin/CJGH2022-3533504.003.gif)
Similar articles
-
Polyethylene glycol 3350 plus electrolytes for chronic constipation: a 2-week, randomized, double-blind, placebo-controlled study with a 52-week open-label extension.J Gastroenterol. 2019 Sep;54(9):792-803. doi: 10.1007/s00535-019-01581-x. Epub 2019 Apr 22. J Gastroenterol. 2019. PMID: 31011797 Free PMC article. Clinical Trial.
-
Low-Dose Linaclotide (72 μg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial.Am J Gastroenterol. 2018 Jan;113(1):105-114. doi: 10.1038/ajg.2017.230. Epub 2017 Aug 22. Am J Gastroenterol. 2018. PMID: 29091082 Free PMC article. Clinical Trial.
-
Linaclotide in Chronic Idiopathic Constipation Patients with Moderate to Severe Abdominal Bloating: A Randomized, Controlled Trial.PLoS One. 2015 Jul 29;10(7):e0134349. doi: 10.1371/journal.pone.0134349. eCollection 2015. PLoS One. 2015. PMID: 26222318 Free PMC article. Clinical Trial.
-
Cochrane Review: Osmotic and stimulant laxatives for the management of childhood constipation (Review).Evid Based Child Health. 2013 Jan;8(1):57-109. doi: 10.1002/ebch.1893. Evid Based Child Health. 2013. PMID: 23878124 Review.
-
Osmotic and stimulant laxatives for the management of childhood constipation.Cochrane Database Syst Rev. 2012 Jul 11;(7):CD009118. doi: 10.1002/14651858.CD009118.pub2. Cochrane Database Syst Rev. 2012. Update in: Cochrane Database Syst Rev. 2016 Aug 17;(8):CD009118. doi: 10.1002/14651858.CD009118.pub3. PMID: 22786523 Updated. Review.
Cited by
-
Radiologically supervised bowel management program outcome in patients with chronic idiopathic constipation.Pediatr Surg Int. 2023 Jul 10;39(1):229. doi: 10.1007/s00383-023-05508-9. Pediatr Surg Int. 2023. PMID: 37428259
-
American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation.Gastroenterology. 2023 Jun;164(7):1086-1106. doi: 10.1053/j.gastro.2023.03.214. Gastroenterology. 2023. PMID: 37211380 Free PMC article.
References
-
- DiPalma J. A., Cleveland M. V., McGowan J., Herrera J. L. A randomized, multicenter, placebo-controlled trial of polyethylene glycol laxative for chronic treatment of chronic constipation. American Journal of Gastroenterology . 2007;102(7):1436–1441. doi: 10.1111/j.1572-0241.2007.01199.x. - DOI - PubMed
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical